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A 43-year-old man underwent nephrectomy for right renal cell carcinoma (cT3aN0M1 (PUL), clear cell
carcinoma). Thereafter, he was treated with sunitinib for lung metastases as the first-line therapy for three
months. Because lung metastases progressed and new bone metastases appeared, nivolumab was started for
the second-line treatment. Although the cancer progression was suppressed by multidisciplinary treatment
combined with systemic immunotherapy and local radiation therapy, he developed severe acute kidney injury
with cortical swelling after eighteen months of nivolumab treatment. A diagnosis of acute interstitial
nephritis induced by nivolumab was made based on biopsy findings. Treatment with prednisolone (1.0
mg/kg daily) led to a rapid improvement in renal function. We must consider the possibility of immune-
related adverse events, especially nivolumab-induced acute kidney injury, even after long-term treatment.
(Hinyokika Kiyo 65 : 157-161, 2019 DOI : 10.14989/ActaUrolJap_65_5_157)
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患 者 : 43歳，男性
主 訴 : 全身倦怠感，四肢浮腫
既往歴 : 十二指腸潰瘍
家族歴 : 特記すべきことなし
現病歴 : 2016年 8月，肺腫瘤の精査目的に行われた
胸部 CT で右腎腫瘍を認め，当科紹介となった．体幹
部造影 CT で，右腎上極に腎周囲脂肪へ浸潤する 8
cm 大の腫瘍に加え，多発肺転移巣を認めた（Fig. 1）．
頭部 CT，骨シンチグラフィでは異常を認めず，
cT3aN0M1 の右腎細胞癌と診断し，2016年 9 月に腹
腔鏡下右腎摘除術を施行した．
組織学的所見は clear cell renal cell carcinoma with
focal sarcomatoid change，grade 3，INF α，v0，ly0 :





Fig. 1. Enhanced contrast CT-scan showed an 8 cm
























検査で Cre 5.6 mg/dl と急性腎機能障害を認めたた
め，原因精査目的に入院となった（Fig. 2A）．
入院時現症 : 血圧 120/86 mmHg，脈拍 93 bpm，体
温 36.8°C，SpO2 99％（room air）
血液検査所見 : WBC 6,960/μ l，Hb 9.0 g/dl，Plt
47.8×104/μ l，TP 7.6 g/dl，Alb 3.2 g/dl，LDH 355
IU/l，ALP 306 IU/l，BUN 65 mg/dl，Cre 5.65 mg/dl，




画像所見 : 腹部単純 CT で，左腎は 1カ月前に比較






































Fig. 2. Clinical course of renal cell carcinoma and creatinine changes before nephritis
(A), and after nephritis (B).
泌62,08,0◆-3
Fig. 3. Histopathological findings of kidney biopsy
revealed the infiltration of lymphocytes,
eosinophils and neutrophils in the interstitial
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Fig. 4. Acute kidney injury associated with immune
checkpoint inhibitors in the studies reviewed.
Table 1. Management of renal toxicity (Based on CTCAE v 4.0 grade)
Grade Serum creatinine Immunotherapy Treatment
Grade 1 Base line×1.0-1.5, ULN×1.0-1.5 Continue Monitor creatinineIf creatinine worsens, treat as grade 2, 3 or 4
Grade 2 Base line×1.5-3.0, ULN×1.5-3.0 Withhold therapy and resume if
symptoms are mild severity (≦
Grade 1)
Administer methylprednisolone 0. 5-1. 0 mg/kg/day
IV or equivalent. Taper over 1 month
Grade 3 Base line×3.0≦, ULN×3.0-6.0
Grade 4 ULN×6.0≦ Permanently discontinue Administer methylprednisolone 0. 5-1. 0 mg/kg/dayIV or equivalent. Taper over 1 month
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